A Randomized, Double-blind, Parallel group, Placebo-controlled Study to investigate the efficacy, safety, and tolerability of ML-004 in adolescents and adults with autism spectrum disorders (ASD)
Sponsor: |
Maplight Therapeutics, Inc. |
Enrolling: |
Male and Female Patients |
Study Length: |
26 Weeks |
Clinic Visits: |
10 |
IRB Number: |
8471 |
U.S. Govt. ID: |
NCT05081245 |
Contact: |
Suvekcha Bhattachan: 914-997-5587 / suvekcha.bhattachan@nyspi.columbia.edu |
This study will examine the possible benefits of an investigational drug called ML-004 in adolescents and adults diagnosed with autism spectrum disorder (ASD). We are currently recruiting adolescent participants (12-17 years). Participation will involve ten visits to the Center for Autism and the Developing Brain in White Plains, NY over a period of 26 weeks. This will allow the study team to assess participants' general health, perform developmental testing and provide study related medical care. Participants will not have to pay for any study related treatments, lab tests or assessments. Participants and Study Partners will receive $100 each in reimbursements for in-clinic study visits and up to $40 in travel reimbursements.
Investigator
Jeremy Veenstra-VanderWeele, MD
Is the participant between the ages of 12 and 17? |
Yes |
No |
Has the participant been diagnosed with Autism Spectrum Disorder? |
Yes |
No |